NDB4S_ANDCR
ID NDB4S_ANDCR Reviewed; 74 AA.
AC A0A0A1I6E7;
DT 01-APR-2015, integrated into UniProtKB/Swiss-Prot.
DT 04-FEB-2015, sequence version 1.
DT 25-MAY-2022, entry version 7.
DE RecName: Full=Antimicrobial peptide AcrAP1;
DE Flags: Precursor;
OS Androctonus crassicauda (Arabian fat-tailed scorpion).
OC Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Chelicerata; Arachnida;
OC Scorpiones; Buthida; Buthoidea; Buthidae; Androctonus.
OX NCBI_TaxID=122909;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], MASS SPECTROMETRY, SYNTHESIS OF 23-40,
RP FUNCTION, MUTAGENESIS OF SER-26; HIS-30; SER-33 AND SER-37, AND AMIDATION
RP AT LYS-40.
RC TISSUE=Venom, and Venom gland;
RX PubMed=25332684; DOI=10.7150/ijbs.9859;
RA Du Q., Hou X., Ge L., Li R., Zhou M., Wang H., Wang L., Wei M., Chen T.,
RA Shaw C.;
RT "Cationicity-enhanced analogues of the antimicrobial peptides, AcrAP1 and
RT AcrAP2, from the venom of the scorpion, Androctonus crassicauda, display
RT potent growth modulation effects on human cancer cell lines.";
RL Int. J. Biol. Sci. 10:1097-1107(2014).
CC -!- FUNCTION: Has antimicrobial activity against the Gram-positive bacteria
CC S.aureus (MIC=8 uM) and the yeast C.albicans (MIC=16 uM). Causes
CC hemolysis on horse erythrocytes (64 uM for 100% hemolysis). Minimum
CC bactericidal concentrations have also been tested against S.aureus and
CC is four-fold higher (MBC=32 uM). {ECO:0000269|PubMed:25332684}.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:25332684}. Target
CC cell membrane {ECO:0000250}. Note=Forms a helical membrane channel in
CC the prey. {ECO:0000250}.
CC -!- TISSUE SPECIFICITY: Expressed by the venom gland. {ECO:0000305}.
CC -!- MASS SPECTROMETRY: Mass=1961.76; Method=Electrospray;
CC Evidence={ECO:0000269|PubMed:25332684};
CC -!- MISCELLANEOUS: Does not show antimicrobial activity against the Gram-
CC negative bacteria E.coli (MIC>250 uM). Does not show effect on four
CC different human cancer cell lines. {ECO:0000269|PubMed:25332684}.
CC -!- SIMILARITY: Belongs to the non-disulfide-bridged peptide (NDBP)
CC superfamily. Short antimicrobial peptide (group 4) family.
CC {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; HG939518; CDN67527.1; -; mRNA.
DR AlphaFoldDB; A0A0A1I6E7; -.
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
DR GO; GO:0050832; P:defense response to fungus; IEA:UniProtKB-KW.
DR GO; GO:0031640; P:killing of cells of another organism; IEA:UniProtKB-KW.
PE 1: Evidence at protein level;
KW Amidation; Antibiotic; Antimicrobial; Cleavage on pair of basic residues;
KW Fungicide; Membrane; Secreted; Signal; Target cell membrane;
KW Target membrane.
FT SIGNAL 1..22
FT /evidence="ECO:0000269|PubMed:25332684"
FT PEPTIDE 23..40
FT /note="Antimicrobial peptide AcrAP1"
FT /id="PRO_0000432592"
FT PROPEP 46..74
FT /evidence="ECO:0000269|PubMed:25332684"
FT /id="PRO_0000432593"
FT MOD_RES 40
FT /note="Lysine amide"
FT /evidence="ECO:0000269|PubMed:25332684"
FT MUTAGEN 26
FT /note="S->K: Shows important increase in antimicrobial
FT activity against E.coli (MIC=8 uM) and slight increase
FT against S.aureus (MIC=4 uM) and C.albicans (MIC=4 uM), as
FT well as slight increase in hemolytic activity (32 uM for
FT 100% hemolysis). Also shows anti-proliferative effects on
FT four cancer cell lines; when associated with K-30; K-33 and
FT K-37."
FT /evidence="ECO:0000269|PubMed:25332684"
FT MUTAGEN 30
FT /note="H->K: Shows important increase in antimicrobial
FT activity against E.coli (MIC=8 uM) and slight increase
FT against S.aureus (MIC=4 uM) and C.albicans (MIC=4 uM), as
FT well as slight increase in hemolytic activity (32 uM for
FT 100% hemolysis). Also shows anti-proliferative effects on
FT four cancer cell lines; when associated with K-26; K-33 and
FT K-37."
FT /evidence="ECO:0000269|PubMed:25332684"
FT MUTAGEN 33
FT /note="S->K: Shows important increase in antimicrobial
FT activity against E.coli (MIC=8 uM) and slight increase
FT against S.aureus (MIC=4 uM) and C.albicans (MIC=4 uM), as
FT well as slight increase in hemolytic activity (32 uM for
FT 100% hemolysis). Also shows anti-proliferative effects on
FT four cancer cell lines; when associated with K-26; K-30 and
FT K-37."
FT /evidence="ECO:0000269|PubMed:25332684"
FT MUTAGEN 37
FT /note="S->K: Shows important increase in antimicrobial
FT activity against E.coli (MIC=8 uM) and slight increase
FT against S.aureus (MIC=4 uM) and C.albicans (MIC=4 uM), as
FT well as slight increase in hemolytic activity (32 uM for
FT 100% hemolysis). Also shows anti-proliferative effects on
FT four cancer cell lines; when associated with K-26; K-30 and
FT K-33."
FT /evidence="ECO:0000269|PubMed:25332684"
SQ SEQUENCE 74 AA; 8679 MW; C879BCBD2220E725 CRC64;
MEIKYLLTVF LVLLIVSDHC QAFLFSLIPH AISGLISAFK GRRKRDLDGQ IDRFRNFRKR
DAELEELLSK LPIY